Introduction: Interleukin-1 receptor-associated kinase 4 (IRAK4) deficiency is animmunodeficiency disorder of the innate immune system resulting from inhibition ofToll-like receptor-mediated pathways.

No single definition of cytokine storm or the cytokine release syndrome is widely accepted, and there is disagreement about how these disorders differ from an appropriate inflammatory response. The ...

We discovered high-titer neutralizing autoantibodies against interleukin-10 in a child with infantile-onset inflammatory bowel disease (IBD), a phenocopy of inborn errors of interleukin-10 signaling.

They postulated that novel therapeutic targets for pelvic pain in endometriosis are regulated by interleukin-1β (IL-1β) via the c-Jun N-terminal kinase (JNK) signaling pathway. IL-1β has been a ...

Please provide your email address to receive an email when new articles are posted on . Interleukin-1 receptor-associated kinase 4 protein levels were elevated in hidradenitis suppurativa (HS)lesions.

SAIDs are a group of multi-system disorders caused by dysfunction in the innate immune system. A number of these SAIDs are mediated by a cytokine called interleukin-1 (IL-1), including the ...

Medically reviewed by Mary Choy, PharmD Key Takeaways Biologic medications help reduce inflammation in ulcerative colitis. If you're new to biologics, infliximab might be your first option for ...

Researchers from Hangzhou Polymed Biopharmaceuticals Inc. have reported the discovery and preclinical evaluation of HPB-092, an FMS-like tyrosine kinase 3 (FLT3) and interleukin-1 receptor-associated ...

A drug–drug interaction study of everolimus (an mTOR inhibitor) and JI-101, an orally active inhibitor of VEGF 2, PDGF, and EphB4 receptors, in patients with advanced urologic tumors. This is an ASCO ...

Biomarkers for early prognostication of outcome in patients with bone-metastatic castration-resistant prostate cancer treated with enzalutamide. This is an ASCO Meeting Abstract from the 2017 ASCO ...

Please provide your email address to receive an email when new articles are posted on . WASHINGTON — Withholding Janus kinase or interleukin-17 inhibitors from patients with rheumatoid arthritis or ...